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ABSTRACT: Monoamine oxidases (MAOs) play an important
role in Alzheimer’s disease (AD) pathology. We report in vivo
comonitoring of MAO activity and amyloid-β (Aβ) plaques
dependent on the aging of live mice with AD, using a two-
photon ﬂuorescence probe. The probe under the catalytic action
of MAO produces a dipolar ﬂuorophore that senses Aβ plaques,
a general AD biomarker, enabling us to comonitor the enzyme
activity and the progress of AD indicated by Aβ plaques. The
results show that the progress of AD has a close correlation with
MAO activity, which can be categorized into three stages: slow
initiation stage up to three months, an aggressive stage, and a
saturation stage from nine months. Histological analysis also
reveals elevation of MAO activity around Aβ plaques in aged mice. The close correlation between the MAO activity and AD
progress observed by in vivo monitoring for the ﬁrst time prompts us to investigate the enzyme as a potential biomarker of AD.
■ INTRODUCTION
Alzheimer’s disease (AD), the most common form of dementia
in the elderly, currently aﬀects over 35 million people
worldwide.1 AD is known to be associated with multiple
etiologies, including genetic vulnerability and environmental
factors. Representative clinical symptoms of AD include
irreversible memory loss, progressive cognitive decline,
disorientation, language impairment, and emotional instability.2
Currently, in vitro monitoring of AD is mostly conducted by
biochemical examination of AD biomarkers such as amyloid-β
(Aβ) peptides in the form of plaques (Aβ plaques) and
intracellular neuroﬁbrillary tangles of hyperphosphorylated tau
(NFTs).3,4 Assays of these two major neuropathological
markers in the cerebrospinal ﬂuid (CSF) seem to be promising,
but such in vitro assays also raise questions in terms of accuracy
and reliability for discrimination of the disease state.5−7
Alternatively, in vivo diagnostic imaging methods for the key
biomarkers are in clinical practice, which include PET (positron
emission tomography), SPECT (single photon emission
computed tomography), and MRI (magnetic resonance
imaging).8,9 Accordingly, several FDA-approved imaging agents
are extensively used in clinical practice and in academia to
understand AD-associated pathology.10 These imaging meth-
ods, however, have high cost, limited accessibility, and time-
consuming data processing procedures. Additionally, excessive
exposure to damaging radiation is a concern with the PET/
SPECT methods.11 Finally, the relatively low resolution of
these imaging techniques limits their ability to yield distinguish-
ing morphological diﬀerences between normal and abnormal
tissues. Therefore, there is a great demand for readily accessible,
convenient, and sensitive diagnostics for AD, in particular by
detecting potential AD biomarkers present outside the brain.
Fluorescence microscopy provides a versatile means in
neuroimaging of AD in animal models, as it oﬀers high
resolution, high sensitivity, low cost, broad availability, and real-
time monitoring in various animals. Such properties oﬀer
precise and accurate data in investigating disease-related
biological processes, in diagnosis and prognosis, and in drug
discovery.11,12 Among the various ﬂuorescence imaging
techniques, two-photon microscopy (TPM) has received
increasing interest in recent years. TPM with near-infrared
laser (NIR) light (700−1000 nm) allows focal point excitation
and provides 3D images with excellent resolution, in addition to
causing less photodamage and photobleaching needed for long-
term imaging.13,14 TPM using NIR light also alleviates the
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common interference from autoﬂuorescence of intrinsic
biomolecules during deep tissue imaging.15 Accordingly, TPM
has been widely used in preclinical research using animal
models.16,17
Recently, a few two-photon probes for Aβ plaques have been
reported (Figure 1a). SAD-1 (Kim et al., 2013)18 and Aβ probe
5 (Ahn et al., 2015)19 showed eﬃcient in vivo TPM imaging
capability toward Aβ plaques in a transgenic AD mouse model.
In search of a convenient diagnostic for AD, we became
interested in identifying biomarkers for AD other than Aβ
plaques. Monoamine oxidases (MAO-A and MAO-B), which
are known to be associated with AD, are such a candidate.
MAOs are a family of FAD-dependent enzymes found in the
outer mitochondrial membrane of neuronal, glial, and other
mammalian cells.20 MAOs catalyze the oxidative deamination
of biogenic amines and play key roles in the metabolism of
neurotransmitters in the central nervous system (CNS).
Dysfunction of MAOs is closely associated with brain disorders
such as AD, Parkinson’s disease (PD),21 and Huntington’s
disease (HD).22 AD and PD are known to be associated with
an elevated level of MAO-B in the cortical and hippocampal
regions of brain.23,24 MAO-B, the predominant isoform in
human brain and mostly localized in glial cells, is known to be
activated with age and in AD, although both the reason and the
mechanism of its upregulation are not understood.25 According
to enzymatic radioimmunoassays performed on post-mortem
human brain tissues, the increased MAO-B activity was ascribed
to an increase in enzyme concentration.26 The upregulated
MAO-B level in AD patients may be due to increased gliosis,
and it has been suggested that the elevated MAO-B activity in
the aging brain and in AD may contribute to cellular
degeneration by the overproduction of hydrogen peroxide, a
byproduct of amine oxidation by the enzyme.27 Treatment with
a MAO-B inhibitor, L-deprenyl (also known as selegiline),
improves PD and also appears to retard the cognitive decline in
AD.28 A growing body of evidence suggests that MAOs play a
major role in aging as well as in age-related neurological
diseases such as AD and PD.
The available evidence suggesting elevation of MAO activity
with AD is all based on in vitro assays of sectioned brain
tissues.29,30 A direct correlation between MAO activity
associated with AD from in vivo assays is lacking. In vivo
monitoring of MAO activity as a function of AD progression,
however, remains a challenging task. In vivo monitoring of
MAO activity along with Aβ plaques is needed to assess their
potential correlation. To date, two-photon probes with the
capability to coimage in vivo Aβ plaques and potential AD
biomarkers such as monoamine oxidase (MAOs),31 β-site
amyloid precursor protein cleaving enzyme (BACE),32,33 or
acetylcholine esterase34 have not been explored. Unambigous
correlation data on biomarkers associated with AD would
provide valuable information in understanding the complex AD
pathology and diagnosing its progression. In this work, we
developed a probe that allows comonitoring of Aβ plaques and
MAO activity in a mouse model of AD, establishing the ﬁrst in
vivo correlation between these two disease markers. We ﬁnd
that MAO activity increases as AD progresses, providing a solid
path for potential diagnosis of AD.
■ RESULTS AND DISCUSSION
Comonitoring strategy. To correlate MAO activity along
with the progress of AD by ﬂuorescence TPM imaging, we
focused on a two-photon probe for Aβ plaques that could be
selectively activated by MAOs. Our earlier investigations
identiﬁed MAO probe 1, which generates benzo[g]imino-
coumarin 2 (IBC 2) as the product of enzymatic oxidation by
MAO. IBC 2 is a ﬂat and elongated dipolar dye which we
reasoned might selectively sense Aβ plaques (Figure 1b), due to
its structural similarity to the known probes.35 Most of the
known ﬂuorescent probes for Aβ plaques also have a dipolar
character, making them weakly emissive outside Aβ plaques but
highly emissive inside Aβ plaques. It should be noted that
although MAO-B is predominantly active in the brain and of
most interest for AD diagnosis, probe 1 senses both MAO-A
and MAO-B.
MAOs transform the aminopropyl moiety of probe 1, which
is nonﬂuorescent, into the corresponding iminium ion
intermediate, which, upon hydrolysis followed by β-elimination,
generates the corresponding hydroxy intermediate, which
immediately condenses with one of the nitrile groups in 1 to
produce a highly ﬂuorescent IBC 2 as the ﬁnal product (Figure
S2). This turn-on type ﬂuorescence response allowed us to
selectively detect MAOs. Enzyme assays with probe 1 as MAO
substrate gave a comparable level of Km (Michaelis−Menten
constant) and kcat (turnover number) values for MAO-A (Km =
70 μM, kcat = 71 min
−1) and MAO-B (Km = 75 μM, kcat = 53
min−1), determined in pH 7.4 HEPES buﬀer. In the case with
natural amine substrates Km values are in the μM range.
36 The
enzymatic transformation of probe 1 into IBC 2 by MAOs is
reasonably fast for bioimaging application: kobs (observed rate
constant with correlation factor R2 > 0.95) = 5.8 s−1 (MAO-A)
and 6.4 s−1 (MAO-B).
Figure 1. Chemical structures and an overall scheme for in vivo TPM imaging. (a) Chemical structures of SAD-1 and Aβ probe 5. (b) In vivo
coimaging scheme of MAO activity and Aβ plaques using probe 1 in live AD mouse model.
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IBC 2 has promising photophysical properties for the in vivo
two-photon imaging application: It has (i) absorption and
ﬂuorescence emission bands in the biological transmission
window37 (one- and two-photon excitation at 450 nm and
∼900 nm, respectively; emission at 600 nm with quantum yield
of 0.63), (ii) suﬃcient two-photon absorbing property (TPACS
= 180 GM),36 (iii) a low molecular weight (MW = 263.10), and
(iv) an optimal lipophilicity value required for BBB
penetration: LogP values are 2.91 ± 0.94 for IBC 2 and 2.77
± 0.80 for MAO probe 1, as calculated by using ACDLab-
ACDLogP software, from which LogBB values obtained are
0.97 for IBC 2 and 0.93 for MAO probe 1. LogBB = (LogP−
0.1725)/2.808.38,39
Upregulated MAO activity in AD mice is expected to
generate a higher level of the enzyme reaction product, IBC 2,
in AD mice relative to healthy mice. IBC 2 is a typical donor
(D)−acceptor (A) type dipolar dye, which has intramolecular
charge transfer (ICT) excited states and is thus sensitive to the
polarity of its surroundings. Thus, it emits weaker ﬂuorescence
in aqueous media (outside the plaques) but enhanced
ﬂuorescence in the hydrophobic and congested environment
of Aβ plaques,40 enabling their selective detection. The
presence of IBC 2 outside Aβ plaques appears to give residual
ﬂuorescence whose intensity is dependent on MAO activity.
Therefore, MAO activity could potentially be directly
correlated with the progress of AD, by comonitoring the
intensity and distribution of the signal from the free probe and
from the probe bound to Aβ plaques (Figure 1b).
In Vitro Aβ Plaque Binding Assay of IBC 2. We ﬁrst
monitored absorption and emission spectal changes of IBC 2
upon treatment with Aβ plaques, the results of which are given
in Figure 2. IBC 2 exhibits an absorption maximum at 450 nm
in either ethanol or PBS buﬀer (Figure 2a), and the
ﬂuorescence maxima appear at 571 nm and at 600 nm in
ethanol and in PBS buﬀer, respectively (Figure 2b). The
polarity inside Aβ plaques is similar to that of ethanol,18 which
suggests that a similar bathochromic shift in the emission
wavelength should occur when IBC 2 is translocated into Aβ
plaques. Indeed, an emission shift (10 nm) along with an
intensity enhancement (>5-fold) was observed when IBC 2 was
introduced to Aβ plaques (Figure 2c). The ﬂuorescence
enhancement is attributed to the more hydrophobic and
congested environment inside Aβ plaques. In contrast, probe 1
showed no change in ﬂuorescence in the presence of Aβ
plaques only. The plaque-binding aﬃnity of IBC 2 was
measured by ﬂuorescence titration over a wide range of Aβ
plaque concentrations (Figure 2d, Figure S3), aﬀording a
dissociation constant of Kd = 32.2 ± 6.4 nM. The ﬂuorescence
titration data shows that 10 μM Aβ plaques accommodate 2
μM IBC 2 (5:1 binding stoichiometry), although such value is
expected to be dependent on the size distribution and
morphology of Aβ plaques prepared. The ﬂuorescence
spectrum of IBC 2 showed little depencence on medium,
yielding comparable spectra in PBS buﬀer, in aCSF (artiﬁcial
cerebrospinal ﬂuid; see the composition in the Supporting
Information), or in aCSF containing BSA (bovin serum
albumin) (Figure S4). Also, the ﬂuorescence emisison of IBC
2 is not inﬂuenced by AD-associated divalent metal ions such as
Cu2+ and Zn2+ (Figure S4).41
Ex Vivo TPM Imaging of Aβ Plaques in Brain Tissues
Using IBC 2. To examine selective staining of Aβ plaques using
IBC 2, we conducted ex vivo TPM imaging of AD mouse brain
Figure 2. In vitro analysis of IBC 2. (a, b) Absorption and emission spectra of IBC 2 (10 μM) in ethanol and PBS buﬀer (pH 7.4), respectively. (c)
Fluorescence spectra of probe 1 (10 μM) and IBC 2 (10 μM) in the presence of Aβ plaques (0−50 μM) in PBS buﬀer (pH 7.4). (d) Saturation
binding curve of Aβ plaques (10 μM) dependent on [IBC 2] (0−15 μM) in PBS buﬀer (pH 7.4). The intensity represents the peak height at the
maximum emission wavelength. All the measurements were conducted at 25 °C after 1 h of mixing under 450 nm excitation. (e) In vitro TPM
images of Aβ plaques in the frontal cortex of 5XFAD mouse brain tissue costained with MeO-X04 (10 μM, 760 nm excitation, detection through
green channel of 500 ± 30 nm) and IBC 2 (10 μM, 850 nm excitation, detection through red channel of 600 ± 30 nm) after 45 min incubation in
aCSF. IBC 2 shows negligible ﬂuorescence at 760 nm excitation (Figure S6). Imaging depth is at the middle of the tissue samples (∼50 μm). Two-
photon laser power was ∼30 mW at the focal point. Scale bar is 20 μm.
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tissues after costaining with MeO-X04,42,43 a reference staining
dye for Aβ plaques. The brain tissue slices were prepared from
a 9-month-old transgenic mouse (5XFAD, tg6799)44 that had
well-developed Aβ plaques. Brain hippocampal tissues were
horizontally sectioned and then immersed in a solution
containing both IBC 2 and MeO-X04 (10 μM for 45 min,
respectively), which were then washed with aCSF medium
prior to imaging (for details, see Supporting Information).
Two-photon excitation at 850 nm provided the best image
quality (see Figure S5 for screening of an optimal in vivo two-
photon excitation wavelength). IBC 2 stained Aβ plaques with
a strong red emission signal, which was colocalized with the
reference dye, conﬁrming that IBC 2 eﬃciently accumulates
into and senses Aβ plaques (Figure 2e).
In Vivo TPM Imaging of Aβ Plaques in Live Mice Using
IBC 2. Given that IBC 2 showed an excellent ability to image
Aβ plaques in vitro, we next performed in vivo imaging
experiments of live AD mice by TPM. A 9-month-old 5XFAD
AD mouse was anesthetized, and a cranial window was installed
by thinned skull surgery (for details, see Supporting
Information). IBC 2 was then injected intraperitoneally (10
mg kg−1) into the mouse, and the distribution of Aβ plaques in
the cortex region was monitored by two-photon excitation at
850 nm (∼50 mW laser power at the focal point). IBC 2 was
readily visualized in the Aβ plaques at depths >600 μm (Figure
3a), demonstrating the ability of IBC 2 to pass the blood−brain
barrier relatively rapidly (for Aβ plaque staining after 1 min:
Figure 3b, indicated by the white arrow). There was negligible
ﬂuorescence detected after 24 h (Figure 3b, Figure S7),
indicating that the probe was rapidly cleared from the
hippocampus. Notably, the imaging capability of IBC 2 is at
least 2× deeper than that of previously reported two-photon
probes for Aβ plaques.18 It is known that Aβ plaques in 5XFAD
mice ﬁrst appear in the deeper layers of the cortex (>500 μm)
and then gradually spread to the entire cortex near the skull
surface (Figure 3c, the purple cloud indicates the main
distribution of Aβ plaques).45 Therefore, a dye that enables
deeper tissue imaging is crucial for in vivo monitoring of AD
progress. Furthermore, the surrounding blood vessels showed
evidence of small amyloid deposits, which may be ascribed to
the cerebral amyloid angiopathy (CAA)46 (Figure 3d, indicated
by the white arrow). This result also highlights the high
sensitivity of IBC 2 for imaging of small amyloid deposits.
Additionally, real-time monitoring of plaque staining was
carried out by separate blood staining with Dextran-Texas-
Red (Figure 3e, Figure S8, Supporting Movie S1). Such long-
term in vivo monitoring was made possible by the high
photostability of IBC 2: When a selected Aβ plaque was
irradiated with the two-photon laser for 60 min even under
Figure 3. In vivo imaging of Aβ plaques using IBC 2. (a) 3D-reconstructed, magniﬁed (20×) ﬂuorescence images of Aβ plaques in the frontal cortex
of transgenic mouse (5XFAD, 9-month-old), obtained after ip injection of IBC 2 (10 mg kg−1; 2 h circulation) by in vivo TPM under excitation at
850 nm with approximately 50 mW laser power at the focal point. Image reveals a plaque at 600 μm depth (along the z-direction) from the surface of
the cortex. The ﬂuorescence from both the green and red channels was collected. The unit scale is 45 μm. (b) In vivo ﬂuorescence images of Aβ
plaques in 5-month-old 5XFAD mouse after ip injection of IBC 2 (10 mg kg−1), obtained by in vivo TPM at diﬀerent time intervals (excitation at 850
nm; 50 mW laser power). Imaging depth was approximately 200 μm. Scale bar is 30 μm. (c) Illustration of brain section and plaque distribution. (d)
CAA (cerebral amyloid angiopathy), observed near the blood vessel (the dark channel) as indicated by the white arrows from the in vivo TPM image
of a 5XFAD (9-month-old) mouse brain. Imaging depth is 200 μm. Scale bar is 30 μm. (e) Snapshot of the video clip for Aβ plaques and blood
vessel in 5XFAD (11-month-old) mouse brain, stained with IBC 2 and Dextran-Texas-Red (70 kDa, 25 mg kg−1 just before imaging), respectively.
The emission from Dextran-Texas-Red was collected with >650 nm ﬁlter under two-photon excitation at 850 nm (50 mW). Scale bar is 50 μm. (f) In
vivo two-photon laser photobleaching assay of a plaque stained with IBC 2 (10 mg kg−1; 9-month-old 5XFAD mouse; after 2 h circulation) and
located at approximately 50 μm depth. Two-photon laser (80 mW; 850 nm) was irradiated for 60 min. Fluorescence intensity was analyzed before
and after 60 min in three diﬀerent detection channels: green (green line, 500 ± 30 nm), red (red line, 600 ± 30 nm), and blue (blue line 420 ± 30
nm). The x-axis and y-axis represent pixels and ﬂuorescence intensity, respectively. (g) Fluorescence OPM images for a sectioned brain tissue (x−z
axis cut) isolated from a mouse after in vivo TPM imaging. Fluorescence was collected in the green channel (500 ± 30 nm) under excitation at 450
nm. Scale bar is 1000 μm. Two cortex regions in the rectangle are magniﬁed (scale bar: 200 μm).
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harsh conditions for organic molecules (850 nm; 80 mW), only
30% of the ﬂuorescence signal was bleached (Figure 3f).
One-photon confocal microscope images were acquired on a
brain tissue section to obtain a wide area image of Aβ plaques
(Figure 3g). This image revealed the Aβ plaques to be
distributed primarily in the 300−1000 μm outer edge of the
cerebral cortex region (magniﬁed image of white box in Figure
3g). The data show that the penetration depth obtained by two-
photon imaging of IBC 2 is suﬃcient to reveal most of the
plaque-related AD pathology in this model.
In Vivo TPM Comonitoring of MAO Activity and Aβ
Plaques in Live Mice Using Probe 1. Given that IBC 2
showed high sensitivity and fast response to Aβ plaques, we
next investigated the ability of probe 1 to comonitor MAO
activity and Aβ plaques in vivo. Probe 1 produces the Aβ
plaque-imaging agent IBC 2 upon reaction with MAOs, and so
probe 1 is a marker of both MAO activity and Aβ plaques.
Probe 1 was intraperitoneally injected (10 mg kg−1) to healthy
(9-month-old, n = 3) and 5XFAD AD mice (2−11-month-old,
n = 2−3), and then a cranial window was installed in each
mouse using the protocol described above. A good cell viability
of probe 1 was conﬁrmed by a cellular metabolism assay.36
After 2 h circulation of the probe, ﬂuorescence images were
acquired through the cranial window under two-photon
excitation conditions. The ﬂuorescence images, collected at
200−300 μm depth from a z-stack (Figure 4a), showed a
distinct increase in the number and size of Aβ plaques as well as
an increase in the background ﬂuorescence signal associated
with MAO activity as the mice aged and AD progressed. IBC 2
generated by MAO activity is responsible for both the
“background” (outside plaques) and Aβ plaque signals. The
ﬂuorescence response was negligible in the healthy mice but
signiﬁcant in the 4-month-old AD mice, and the intensity
became more substantial in the older mice. Moreover, CAA
species appeared in the 4-month-old mice (Figure 4a, indicated
by the white arrow). Large Aβ plaques became abundant in the
7-month-old mice. Additionally, we noted substantial spreading
of the plaques through the entire cortex at the later stages of
AD.
The ﬂuorescence intensity of the background region and in
the Aβ plaques was extracted separately from the imaging data
by choosing suitable threshold values, which was plotted as the
bar graph shown in Figure 4b. Both the background signal and
the plaque signal gradually increased as the age of the mice
Figure 4. In vivo TPM coimaging of MAO activity and Aβ plaques using probe 1. (a) In vivo ﬂuorescence images (from z-stack, magniﬁed 20×) of
the frontal cortex region of transgenic (5XFAD, 2−11-month-old, n = 2−3) and healthy mice (9-month-old, n = 3), obtained after ip injection of
probe 1 (10 mg kg−1, 2 h circulation) by TPM under excitation at 850 nm with approximately 50 mW laser power at the focal point. The images
were acquired at 200−300 μm depth (along the z-direction) from the surface of the cortex. The ﬂuorescence from both the green and red channels
was collected. The scale bar is 60 μm. (b) Plots of the average ﬂuorescence intensity of Aβ plaques and background images in panel a, respectively
(the background bar starts from the bottom). (c) A plot of the background ﬂuorescence intensity versus the plaque volume (μm3) per mm3. Those
values were obtained from the in vivo two-photon z-stacked images for the frontal cortex of 5XFAD AD mouse (2−11-month old, n = 5) treated with
probe 1 (10 mg kg−1, 2 h circulation). Each point indicates correlated average values of the background ﬂuorescence intensity and the plaque
volume, which were calculated using Zen 2011 software (Carl Zeiss Inc.) and Volocity software (PerkinElmer).
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increased, suggestive of a close correlation. Also, the back-
ground ﬂuorescence intensity with respect to the plaque
volume shows a rough but apparent proportionality (Figure 4c,
2−11-month-old 5XFAD mice, n = 5, number of z-stacked
images = 15). The in vivo coimaging data unambiguously
establish that MAO activity increases as AD progresses. It
should be noted that the background signal only approximately
represents the MAO activity, because it does not account for
the quantity of IBC 2 taken up by the Aβ plaques. This quantity
scales with the number and the volume of Aβ plaques, which
depend on the age of the animal. The total volume of plaques is
much less than that of the background region. If we assume that
the concentration of IBC 2 in the plaques is not much greater
than that in the background region, we can estimate that the
background signal represents most of the IBC 2 produced by
enzymatic activity. The close correlation between the back-
ground signal and the plaque signal thus indicates that MAO
activity is highly correlated with the progress of AD. Figure 4b
shows that the progress of AD can be categorized into three
stages: a slow initiation stage up to three months, a subsequent
aggressive stage, and then a saturation stage after nine months.
Above all, the in vivo correlation between MAO activity and AD
progress suggests that monitoring of MAO activity may be an
alternate means to follow the progress of AD. The production
of IBC 2 in the AD mouse brain was conﬁrmed by MALDI-
TOF analysis of the chemical extracts isolated from the brain
(see Methods in Supporting Information) (Figure S10).
We further conducted control experiments with the late stage
AD mice (9-month-old, n = 3) that were fed a MAO inhibitor,
selegiline.47 In this case, we observed signiﬁcantly reduced
signal both from the background and from the plaques,
indicative of reduced production of IBC 2 due to inhibition of
MAO activity (Figure 4, Figure S11).
Histological Staining of MAOs and Their Activity
Associated with Aβ Plaques. Along with the in vivo imaging,
we also conducted ex vivo assays of MAOs and Aβ plaques in
the 5XFAD mouse brain by histological tissue staining. We
mainly analyzed MAO-B activity because it is the major
isoenzyme in AD pathology.31 Each of the sectioned brain
tissues (3- and 9-month-old) was incubated with a primary
MAO-B antibody followed by an Alexa Fluoro 488 dye-
conjugated secondary antibody (λem = 500−550 nm, green) for
staining MAO-B. At the same time, MeO-X04 (λem = 420−500
nm) was used to stain the Aβ plaques, whose images were
pseudocolored in red to improve the contrast. The costaining
results showed bright green ﬂuorescence responsible for the
quantity of MAO-B around Aβ plaques (Figure 5a). Both the
green and red images became brighter (2−3 times) in the
sample from the older mouse (Figure 5b), indicative of a higher
level of MAO-B in the aged/AD-progressed mouse.
Next, we quantiﬁed the total concentration of MAO-B by
Western blot analysis. The blots of brain tissue samples from
healthy and 5XFAD mice (3- and 9-month-old, n = 3,
respectively) were incubated with primary antibodies (anti-
Aβ, anti-MAO-B, anti-GAPDH) and consequent secondary
antibodies. Interestingly, the results indicated that there was no
signiﬁcant diﬀerence in the MAO-B concentration in either the
healthy or the AD mice (Figure 5c, Figure S12). According to
Figure 5. Histological staining of MAOs and their activity associated with Aβ plaques. (a) Histological staining of brain slices in the frontal cortex of
transgenic mouse (5XFAD, 3- and 9-month-old, n = 3 for each sample) costained with a MAO-B antibody (excitation at 499 nm; detection at 500−
550 nm) and MeO-X04 (10 μM; excitation at 400 nm and detection at 420−500 nm, red pseudocolored to improve the contrast). Scale bar is 20
μm. (b) Relative ﬂuorescence intensity of Aβ plaques (red-colored, imaged with MeO-X04) and MAO-B (green-colored, imaged with MAO-B
antibody) shown in panel a. The relative intensity and standard deviation were calculated using ImageJ software (NIH, USA) at 10 diﬀerent ROIs
(area: 50 μm2) on the red and green signal region, respectively. (c) Western blots of MAO-B concentration for the brain tissue samples of healthy
(littermate; 3- and 9-month-old, n = 3, respectively) and 5XFAD (3- and 9-month-old, n = 3, respectively) mice. GAPDH is a loading control for the
blot. (d) Activity assay of MAO-B in U373 astrocytoma cells treated with Aβ1−42 peptide (1 μM and 5 μM, respectively). Control: without Aβ
peptide. The ﬂuorescence intensity corresponded to the H2O2 concentration, a side product of MAO’s catalytic action (see Supporting Information
for the experimental protocol).
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previous enzymatic radioimmunoassays performed on post-
mortem human brain tissues, the increased MAO-B activity in
AD patients was ascribed to an increase in enzyme
concentration, not to elevated enzyme activity.26 Our in vivo
assays in the mouse model suggest that not only the local
concentration of MAO-B but also its activity increase as AD
progresses.
We also checked the elevation of MAO activity in the
presence of Aβ peptides. U373 human astrocytoma cells were
treated with Aβ peptides at diﬀerent concentations (fragment
1−42),48 and MAO activity was followed by ﬂuorimetric
monitoring of H2O2, generated as a side product of the
enzymatic oxidative deamination. The results showed a
substantial increase in MAO activity in the presence of Aβ
peptides, in corroboration with the previous report49,50 (Figure
5d for MAO-B activity assay, Figure S13 for MAO-A/B activity
assay). Thus, we conclude that the accumulation of MAOs
around Aβ plaques causes activation of the enzyme, which
becomes more active as AD progresses.
■ CONCLUSION
In conclusion, in vivo comonitoring of MAO activity along with
amyloid-β plaques in live mice with AD was demonstrated for
the ﬁrst time. A reaction-based two-photon MAO probe
enabled this comonitoring, as its enzyme reaction product can
pass the blood−brain barrier and sense amyloid-β plaques to a
depth of 600 μm. The in vivo deep-tissue imaging results
showed a distinctive age-dependent ﬂuorescence increment for
both amyloid-β plaques and an increase in the background
enzymatic activity (outside the plaques). The close correlation
categorizes the progress of AD in mice into three apparent
stages: a slow initiation stage from birth to three months, a
subsequent aggressive stage, and then a saturation stage after
nine months. Histological staining data showed greater enzyme
activity around Aβ plaques in aged AD mice. The close in vivo
correlation between MAO activity and progress of AD indicates
that further investigation of the enzyme as a potential
biomarker of AD is warranted.
■ METHODS
General Information. The chemical reagents were
purchased from Aldrich or TCI. Commercially available
reagents were used without further puriﬁcation. Anhydrous
solvents for organic synthesis were prepared by passing through
a solvent puriﬁcation tower. All reactions were performed
under argon atmosphere unless otherwise stated. Thin-layer
chromatography (TLC) was performed on precoated silica gel
60F-254 glass plates. UV/vis absorption spectra were obtained
using a HP 8453 UV/vis spectrophotometer. Fluorescence
emission spectra were recorded on a PTI (Photon Technical
International) ﬂuorescence system using a 1 cm standard quartz
cell.
In Vitro Assay of Probe 1 and IBC 2. Aβ42 (Sigma-
Aldrich, A9810, molecular weight = 4514.04, 1 mg) was
dissolved in PBS buﬀer (10 mM, pH 7.4) to a ﬁnal
concentration of 100 μM. This solution was incubated in an
e-tube shaker (60 rpm, F1 mode of SLRM-2M, MyLab Corp.)
at 25 °C for 3 days, and used for in vitro assay directly.
Incubation of aggregated Aβ with probe 1 or IBC 2 was carried
out under the same incubating conditions for 1 h. A stock
solution (10 mg mL−1) of bovine serum albumin (BSA,
Promega, R396D) was prepared in PBS buﬀer (10 mM, pH
7.4). The composition of artiﬁcial cerebrospinal ﬂuid (aCSF)
was NaCl (124 mM), KCl (3 mM), NaH2PO4 (1.25 mM),
MgCl2 (1 mM), NaHCO3 (36 mM), D-glucose (10 mM),
CaCl2 (2 mM), 95% O2, and 5% CO2 (by bubbler).
5XFAD Transgenic Mice. 3−11-month-old 5XFAD Tg
mice (Tg6799, Stock No. 006554) purchased from The
Jackson Laboratory (Bar Harbor, ME) were used for ex vivo/
in vivo one-photon/two-photon imaging, immunohistochemis-
try, and Western blot experiments. Five mutations, human APP
695 (Swedish, Florida, and London) and human Presenilin 1
(M146L and L286 V), related with familial Alzheimer’s disease
(FAD) were expressed in 5XFAD mice. With these mutants,
5XFAD mice produced amyloid-β 42 (Aβ42) rapidly and
accordingly amyloid plaques appeared from 2-month-old
mouse in the frontal cortex (layer 5) and the subiculum.
Especially in the frontal cortex, amyloid plaques were spread
from layer 5 to layer 1 as growing. Neuronal cell deaths and
glial cell activations were also detected with deposits of
plaques.45 Animal maintenance and experiments were con-
ducted under “the Animal Care and Use Guidelines of Seoul
National University”.
Ex Vivo TPM Imaging. 5XFAD Tg mice were sacriﬁced by
cervical dislocation, and the brain was immediately extracted.
The isolated brain was ﬁxed in a stage of vibrating blade
microtome (Leica, Nussloch, Germany) ﬁlled with artiﬁcial
cerebrospinal ﬂuid (aCSF) with oxygen bubbling (95% O2, 5%
CO2). Horizontally sectioned brain hippocampal tissues were
immersed in a solution containing IBC 2 (10 μM) and
Methoxy-X04 (10 μM) for 45 min in the living stage, and then
they were washed with aCSF. During two-photon imaging,
aCSF (95% O2, 5% CO2) was continuously supplied at 33 °C
to tissues using a peristaltic pump (Gilson Inc., Middleton, WI,
USA) with a ﬂuidic inline heater (Live cell instrument, Seoul,
Korea).
Thinned Skull Surgery. Thinned skull surgery was
performed for in vivo two-photon imaging. Anesthetized mice
with the mixture of Zoletil 50 (Virbac, Carros, France) and
Rompun (Bayer Korea, Seoul, Korea) (1.2 mL kg−1, intra-
muscular injection) were ﬁxed on a customized heating plate
(37 °C; Live cell instrument, Seoul, Korea). Subsequently,
dexamethasone (0.2 mg kg−1, im) was injected to prevent
inﬂammation. The mouse scalp was sterilized with ethanolic
water (70%). A region of 0.5−1 mm relative to bregma was
chosen, and the skull was ground smoothly with a microdrill
down to the skull depth of about 30 μm. When the surgery was
completed, we dropped cyanoacrylate and attached a round
coverslip (5 mm). Lastly dental cement was applied to the
emerged region.
In Vivo TPM Imaging. Two-photon microscopy (LSM 7
MP; Carl Zeiss Inc., Goettingen, Germany) equipped with
titanium−sapphire femtosecond laser (Chameleon Ultra;
Coherent, Santa Clara, CA), and 20× water immersion
objective lens (W Plan-Apochromat 20×/1.0 DIC M27 70
mm, Carl Zeiss Inc. Germany) was used for in vivo imaging.
Probe 1 or IBC 2 was intraperitoneally injected (10 mg kg−1)
into mice (2−11-month-old 5XFAD Tg mice and 9-month-old
litter mates (WT)) 2 h before imaging. In addition, Dextran-
Texas-Red (70 kDa) was intravenously injected for blood vessel
staining (25 mg kg−1) just before imaging. The laser power was
limited to 70 mW to avoid the damage associated with
phototoxicity for in vivo mouse brain imaging as well as to
minimize autoﬂuorescence from tissues. Zen 2011 software
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(Carl Zeiss Inc.) and Volocity software (PerkinElmer) were
used for image analysis and 3D-reconstructed images.
MAO Inhibition Assay with Selegiline. A group of AD
mice (9−10-month old, n = 3, respectively) were treated with
selegiline (MAO inhibitor, 10 mg/150 mL in water, 1 week, ad
libitum).48 Imaging experiments were conducted by following
the same protocol used for the in vivo two-photon imaging. P-
value: * <0.05, ** <0.01, *** <0.001, n = 3−4 per group.
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